Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Tetanus-Pipeline Review, H1 2015

Tetanus-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Tetanus-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Tetanus-Pipeline Review, H1 2015', provides an overview of the Tetanus's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Tetanus

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Tetanus and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Tetanus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Tetanus pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Tetanus

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Tetanus pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Tetanus Overview 9

Therapeutics Development 10

Pipeline Products for Tetanus-Overview 10

Pipeline Products for Tetanus-Comparative Analysis 11

Tetanus-Therapeutics under Development by Companies 12

Tetanus-Therapeutics under Investigation by Universities/Institutes 14

Tetanus-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Tetanus-Products under Development by Companies 19

Tetanus-Products under Investigation by Universities/Institutes 21

Tetanus-Companies Involved in Therapeutics Development 22

Beijing Minhai Biotechnology Co., Ltd 22

Bharat Biotech International Limited 23

Biological E. Limited 24

Daiichi Sankyo Company, Limited 25

Green Cross Corporation 26

Indian Immunologicals Limited 27

LG Life Sciences, Ltd. 28

Novartis AG 29

Panacea Biotec Limited 30

Prometheon Pharma, LLC 31

Sanofi 32

Sanofi Pasteur SA 33

Serum Institute of India Limited 34

Sinovac Biotech Ltd. 35

Zydus Cadila Healthcare Limited 36

Tetanus-Therapeutics Assessment 37

Assessment by Monotherapy Products 37

Assessment by Combination Products 38

Assessment by Target 39

Assessment by Route of Administration 41

Assessment by Molecule Type 43

Drug Profiles 45

(diphtheria + tetanus + pertussis (acelluar) + poliovirus (types 1, 2 ,3)) vaccine-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

diphtheria + pertussis + tetanus vaccine-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

diphtheria + pertussis + tetanus vaccine-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

diphtheria + tetanus + pertussis (acellular) vaccine-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

diphtheria + tetanus + pertussis (acellular) vaccine-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

diphtheria + tetanus+ pertussis (whole cell) vaccine-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

diphtheria + tetanus + pertussis (whole-cell) vaccine-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

diphtheria + tetanus vaccine-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

DTaP Vaccine-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

GC-1107-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

GC-3111A-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

tetanus + diphtheria + pertussis (acellular) vaccine-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

tetanus vaccine-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

tetanus vaccine-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

tetanus vaccine-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

tetanus vaccine-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

VN-0103-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

Tetanus-Recent Pipeline Updates 74

Tetanus-Dormant Projects 75

Tetanus-Discontinued Products 77

Tetanus-Product Development Milestones 78

Featured News & Press Releases 78

Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program 78

Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur's Investigational Pediatric Hexavalent Vaccine 78

Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age 79

Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 79

Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 80

Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 81

Jun 22, 2012: Sanofi Pasteur's Hexaxim Receives Positive Opinion From European Medicines Agency 82

Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis 83

Jun 13, 2005: U.S. FDA Licenses sanofi pasteur's ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis 83

Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine 84

Appendix 85

Methodology 85

Coverage 85

Secondary Research 85

Primary Research 85

Expert Panel Validation 85

Contact Us 85

Disclaimer 86

List of Tables

Number of Products under Development for Tetanus, H1 2015 10

Number of Products under Development for Tetanus-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Comparative Analysis by Unknown Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Products under Investigation by Universities/Institutes, H1 2015 21

Tetanus-Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 22

Tetanus-Pipeline by Bharat Biotech International Limited, H1 2015 23

Tetanus-Pipeline by Biological E. Limited, H1 2015 24

Tetanus-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 25

Tetanus-Pipeline by Green Cross Corporation, H1 2015 26

Tetanus-Pipeline by Indian Immunologicals Limited, H1 2015 27

Tetanus-Pipeline by LG Life Sciences, Ltd., H1 2015 28

Tetanus-Pipeline by Novartis AG, H1 2015 29

Tetanus-Pipeline by Panacea Biotec Limited, H1 2015 30

Tetanus-Pipeline by Prometheon Pharma, LLC, H1 2015 31

Tetanus-Pipeline by Sanofi, H1 2015 32

Tetanus-Pipeline by Sanofi Pasteur SA, H1 2015 33

Tetanus-Pipeline by Serum Institute of India Limited, H1 2015 34

Tetanus-Pipeline by Sinovac Biotech Ltd., H1 2015 35

Tetanus-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 36

Assessment by Monotherapy Products, H1 2015 37

Assessment by Combination Products, H1 2015 38

Number of Products by Stage and Target, H1 2015 40

Number of Products by Stage and Route of Administration, H1 2015 42

Number of Products by Stage and Molecule Type, H1 2015 44

Tetanus Therapeutics-Recent Pipeline Updates, H1 2015 74

Tetanus-Dormant Projects, H1 2015 75

Tetanus-Dormant Projects (Contd..1), H1 2015 76

Tetanus-Discontinued Products, H1 2015 77

List of Figures

Number of Products under Development for Tetanus, H1 2015 10

Number of Products under Development for Tetanus-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 37

Assessment by Combination Products, H1 2015 38

Number of Products by Top 10 Targets, H1 2015 39

Number of Products by Stage and Top 10 Targets, H1 2015 40

Number of Products by Top 10 Routes of Administration, H1 2015 41

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 42

Number of Products by Top 10 Molecule Types, H1 2015 43

Number of Products by Stage and Top 10 Molecule Types, H1 2015 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Beijing Minhai Biotechnology Co., Ltd

Bharat Biotech International Limited

Biological E. Limited

Daiichi Sankyo Company, Limited

Green Cross Corporation

Indian Immunologicals Limited

LG Life Sciences, Ltd.

Novartis AG

Panacea Biotec Limited

Prometheon Pharma, LLC

Sanofi

Sanofi Pasteur SA

Serum Institute of India Limited

Sinovac Biotech Ltd.

Zydus Cadila Healthcare Limited

Tetanus Therapeutic Products under Development, Key Players in Tetanus Therapeutics, Tetanus Pipeline Overview, Tetanus Pipeline, Tetanus Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com